Skip to content

Octreotide acetate

Bynfezia Pen, Mycapssa, Sandostatin, Sandostatin Lar (octreotide acetate) is a protein pharmaceutical. Octreotide acetate was first approved as Bynfezia pen on 1988-10-21. It is used to treat acromegaly, adenoma, diarrhea, pancreatic neoplasms, and pituitary neoplasms in the USA. Sandostatin's patents are valid until 2036-02-03 (FDA).
Trade Name Bynfezia Pen, Mycapssa, Sandostatin, Sandostatin Lar
Common Name Octreotide acetate
Indication acromegaly, adenoma, diarrhea, pancreatic neoplasms, pituitary neoplasms
Drug Class Peptides: inhibition of growth hormone release
Octreotide acetate
Get full access now